Heart Failure Society of America (HFSA) 2025
September 26-29, 2025 | Minneapolis, MN, USA
The material below is to support scientific exchange. Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Efficacy of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy by baseline health status and quality of life
Outcomes of the HELIOS-B monotherapy population: A post-hoc analysis censoring data following tafamidis initiation
Vutrisiran leads to a reduction of gastrointestinal adverse events in patients with ATTR-CM: A post-hoc analysis from HELIOS-B
